Bariatrics Clinical Trial - Rhythm Pharmaceuticals RM-493-014

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03013543

CONDITION(S): Pro-opiomelanocortin (POMC) Deficiency Obesity Leptin Receptor Deficiency Obesity Bardet-Biedl Syndrome Alstrom Syndrome - TRIAL: Rhythm Pharmaceuticals RM-493-014 - The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity, including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alström syndrome.

Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

Drug

Setmelanotide

Trial Type

Interventional

Phase

Phase 2

Condition

Pro-opiomelanocortin (POMC) Deficiency Obesity Leptin Receptor Deficiency Obesity Bardet-Biedl Syndrome Alstrom Syndrome Smith-Magenis Syndrome

Keywords

Weight loss | Bariatrics